Ponesimod is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/08/2021|
|Rapid review completed||08/10/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that ponesimod (Ponvory®) not be considered for reimbursement at the submitted price. *|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.